BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 24200492)

  • 21. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro].
    Liu CG; Luo QX; Ling TY; Mo YY; Cheng ZL; Huang SG; Mo H
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of RANK/RANKL/OPG gene polymorphisms in aggressive periodontitis.
    Soedarsono N; Rabello D; Kamei H; Fuma D; Ishihara Y; Suzuki M; Noguchi T; Sakaki Y; Yamaguchi A; Kojima T
    J Periodontal Res; 2006 Oct; 41(5):397-404. PubMed ID: 16953816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts.
    Persson E; Lerner UH
    J Cell Biochem; 2011 Dec; 112(12):3732-41. PubMed ID: 21815197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
    Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
    Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of hydrogen sulphide on the expression of osteoprotegerin and receptor activator of NF-κB ligand in human periodontal ligament cells induced by tension-force stimulation.
    Liao C; Hua Y
    Arch Oral Biol; 2013 Dec; 58(12):1784-90. PubMed ID: 24200305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
    J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular mechanism of bone remodelling during mandibular distraction osteogenesis in rats].
    Zhu WQ; Wang X; Wang XX; Wang ZY
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2007 Dec; 42(12):729-32. PubMed ID: 18476557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
    Armada L; Marotta Pdos S; Pires FR; Siqueira JF
    J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histamine contributes to increased RANKL to osteoprotegerin ratio through altered nuclear receptor 4A activity in human chondrocytes.
    Marzaioli V; McMorrow JP; Angerer H; Gilmore A; Crean D; Zocco D; Rooney P; Veale D; Fearon U; Gogarty M; McEvoy AN; Stradner MH; Murphy EP
    Arthritis Rheum; 2012 Oct; 64(10):3290-301. PubMed ID: 22674155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand.
    Wang QP; Yang L; Li XP; Xie H; Liao EY; Wang M; Luo XH
    Bone; 2012 Sep; 51(3):515-23. PubMed ID: 22634178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.
    Galeone A; Brunetti G; Rotunno C; Oranger A; Colucci S; de Luca Tupputi Schinosa L; Zallone A; Grano M; Paparella D
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e141-7. PubMed ID: 23671202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variations in the genes encoding receptor activator nuclear factor κ B (RANK), receptor activator nuclear factor κ B ligand (RANKL) and osteoprotegerin (OPG) in patients with psoriasis and psoriatic arthritis: a case-control study.
    Assmann G; Pfoehler C; Simon P; Pfreundschuh M; Tilgen W; Wieczorek S
    J Dermatol; 2011 Jun; 38(6):519-23. PubMed ID: 21352301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Regulation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin expression by prostaglandin E2 in osteoblastic-like cells].
    Wang BL; Zheng F; Qiu MC
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1992-6. PubMed ID: 19062743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.